Cloramfenicol (Chloramphenicol) API Manufacturers & Suppliers

Chloramphenicol (CAS number 56-75-7) is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae in 1947 and currently produced by synthetic methods. It belongs to the chemical class of nitrobenzenes, characterized by a benzene ring bearing a nitro group. Chloramphenicol exhibits bacteriostatic activity, though bactericidal effects may occur at high concentrations or against highly susceptible microorganisms.

Clinically, chloramphenicol has been used primarily for the treatment of cholera by targeting and destroying Vibrio cholerae, including strains resistant to tetracycline. It is also formulated as ophthalmic preparations such as eye drops and ointments to manage bacterial conjunctivitis. Due to serious adverse effects, notably the risk of irreversible aplastic anemia, systemic oral chloramphenicol products have been withdrawn by the FDA. Consequently, its use is now largely limited to severe, life-threatening infections, including typhoid fever, when alternative agents are ineffective or contraindicated.

Pharmacodynamically, chloramphenicol inhibits bacterial protein synthesis by reversibly binding to the L16 protein component of the 50S ribosomal subunit. This interaction suppresses peptidyl transferase activity, preventing peptide bond formation and thus halting bacterial growth. Its lipophilic nature facilitates penetration through bacterial membranes, allowing intracellular access to ribosomal targets.

Regarding absorption, distribution, metabolism, and excretion (ADME), chloramphenicol is well absorbed from the gastrointestinal tract when administered systemically and widely distributed in body tissues and fluids, including the central nervous system. Hepatic metabolism is significant, involving cytochrome P450 enzymes such as CYP2C19 and CYP3A isoforms, through which chloramphenicol acts as an inhibitor. Renal excretion of metabolites occurs subsequently. The drug’s interaction with multiple cytochrome P450 enzymes warrants attention in polypharmacy scenarios to mitigate potential drug interactions.

Safety concerns focus on hematological toxicity, specifically dose-dependent bone marrow suppression and the rare but potentially fatal aplastic anemia. Accordingly, careful monitoring of blood counts is essential during therapy, and topical application routes are preferred to reduce systemic exposure where clinically appropriate.

Notable pharmaceutical formulations include topical ophthalmological products used globally for bacterial eye infections. However, systemic oral formulations are restricted or withdrawn in several regulatory jurisdictions due to safety profiles.

From an API procurement standpoint, chloramphenicol requires stringent quality control to ensure purity and absence of impurities known to potentiate toxicity. The synthetic production route facilitates batch-to-batch consistency and scalability. Sourcing should prioritize manufacturers compliant with current Good Manufacturing Practices (cGMP) and possessing validated analytical methods for residual solvents and related substances. Additionally, suppliers should provide comprehensive documentation to support regulatory submissions and risk assessments essential for pharmaceutical development and manufacturing.